Interpace Biosciences Inc (PDII) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Interpace Biosciences Inc   (PDII)


Interpace Biosciences Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Interpace Biosciences Inc's ROI in the second quarter of 2026?
Interpace Biosciences Inc achieved a return on average invested assets (ROI) of 104.17 % in its second quarter of 2026, this is above PDII's average return on investment of -30.58%.
Interpace Biosciences Inc invested over the 12 months ending in its second quarter of 2026 $23 million

ROI decreased relative to the period ending Mar 31 2026, due to the decline in net income.

Within the Healthcare sector 12 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 32 to 33.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 494.95 % 594.87 % - - -
Y / Y Net Income Change TTM 372.04 % 200.08 % 294.21 % 43.93 % 151.16 %
Investment (TTM) in Millions 30 29 29 6 5
Return On Investment (TTM) 104.17 % 136.19 % 214.5 % 93.2 % 131.3 %
PDII's Overall Ranking # 33 # 32 # 29 # 53 # 16
Seq. Investment Change TTM 35.15 % 51.56 % 121.99 % 30.84 % 57.84 %
Seq. Net Income Change TTM 3.37 % -3.77 % 410.91 % -7.12 % -34.28 %
Net Income (TTM) in Millions 24 24 25 5 5

PDII Company Profile >> Back to PDII Roi Comparisons >> See Annual PDII Return On Investment



Return On Investment PDII's Ranking
Within: No.
Industry # 4
Sector # 13
Overall # 33

Return On Investment Statistics
High Average Low
1146.96 %
-30.58 %
-665.36 %
(Dec 31 2024)   (Jun 30 2021)







Financial Statements
Interpace Biosciences Inc's II. Quarter Investments $ 30 Millions PDII's Balance sheet
Interpace Biosciences Inc's II. Quarter Income $ 0 Millions Quarterly PDII's Income Statement
PDII's Income by Division See PDII's Income by Division


PDII Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 28 3 -6 2 20
Y / Y Investment Growth 834.64 % - - -91.34 % -
Net Income in Millions 25 7 1 -22 -15
Y / Y Net Income Growth 266.68 % 735.66 % - - -
Annual Return On Investment 87.82 % 223.85 % - -1294.69 % -76.27 %


Annual Roi Comment
In the fiscal year 2025 ROI deteriorated to 87.82 %, despite net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PDII's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PDII's Competitors
Subscribers only: Roi for Interpace Biosciences Inc's Suppliers
Subscribers only: Return On Investment for PDII's Customers

Other Ratios
PDII's Roa PDII's Inventory Turnover Ratio PDII's Growth Rates PDII's Dividend Statistics
PDII's Profitability Ratios PDII's Asset Turnover Ratio PDII's Dividend Growth
PDII's Roe PDII's Valuation Ratios PDII's Financial Strength Ratios PDII's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Omeros Corporation  198.34 %
Elutia Inc   191.75 %
Sanuwave Health Inc   167.92 %
Vor Biopharma Inc   162.71 %
Capforce Inc   161.42 %
Kyntra Bio Inc   157.74 %
Silexion Therapeutics Corp  127.60 %
Quince Therapeutics Inc   112.49 %
Pulmatrix Inc   108.83 %
Interpace Biosciences Inc   100.71 %
Arbutus Biopharma Corp  99.18 %
Rigel Pharmaceuticals Inc  89.00 %
Oncotelic Therapeutics Inc   87.35 %
Actinium Pharmaceuticals Inc  84.38 %
Exelixis Inc   82.05 %
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %

Date modified: 2026-08-12T20:40:36+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.